Form 4: Insider Acquires CAMP Shares via 10b5-1 Plan

Andrew J. Schwab, a Director and 10% owner of Camp4 Therapeutics Corp, acquired 2,941,176 shares of common stock at $1.53 per share through a pre-arranged 10b5-1 plan.

Summary

• Andrew J. Schwab, a Director and 10% owner of Camp4 Therapeutics Corp (CAMP), acquired 2,941,176 shares of common stock.
• The transaction occurred on September 11, 2025, at a price of $1.53 per share.
• The acquisition was made indirectly through 5AM Ventures VII, L.P., and was executed under a Rule 10b5-1 pre-arranged trading plan.
• Following this transaction, Schwab's indirect beneficial ownership includes 2,941,176 shares via 5AM Ventures VII, L.P., 2,625,145 shares via 5AM Ventures VI, L.P., and 302,770 shares via 5AM Opportunities II, L.P., totaling 5,869,091 shares.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of shares by a director and 10% owner, Andrew J. Schwab, indicates strong insider confidence in Camp4 Therapeutics Corp's future, contributing to a positive sentiment.

Positives

• A Director and 10% owner, Andrew J. Schwab, increased his beneficial ownership in Camp4 Therapeutics Corp by acquiring 2,941,176 shares.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which is a transactional report.

Industry Context

This insider transaction reflects an individual's investment decision within the biotechnology sector, rather than a broader industry trend or competitive analysis.

Related Party Transactions

• Andrew J. Schwab, a Director and 10% owner, acquired 2,941,176 shares of common stock indirectly through 5AM Ventures VII, L.P., an entity where he is a managing member.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling confidence from a significant investor and director in the company's prospects.

Key Dates

Recommendation

The acquisition of a significant block of shares by a director and 10% owner, Andrew J. Schwab, signals strong insider confidence in Camp4 Therapeutics Corp. This positive indicator, especially when executed under a Rule 10b5-1 plan, suggests a deliberate investment strategy. However, a single insider transaction, without further fundamental analysis of the company's financial health, strategic direction, and market conditions, is insufficient to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor for further developments and broader market context.

Keywords

Camp4 Therapeutics, CAMP, Andrew J. Schwab, Insider Trading, Form 4, Stock Acquisition, 10b5-1 Plan, 5AM Ventures, Biotechnology, Pharmaceuticals